Stockscreener 앱 받기
68.05
2.79%
1.85
시간 외 거래:
68.05
전일 마감가:
$66.20
열려 있는:
$67.64
하루 거래량:
2.40M
Relative Volume:
1.16
시가총액:
$7.96B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
22.53
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
+4.05%
1개월 성능:
-1.35%
6개월 성능:
+11.21%
1년 성능:
+16.38%
1일 변동 폭
$65.00
$69.93
1주일 범위
$63.84
$69.93
52주 변동 폭
$42.01
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
68.05 | 7.74B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme Therapeutics (NASDAQ:HALO) Releases Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View - TradingView
HALO Receives Maintained Rating and Raised Price Target by Citiz - GuruFocus
Citizens raises Halozyme Therapeutics stock price target to $92 on strong royalty growth - Investing.com Nigeria
Hussman Strategic Advisors Inc. Grows Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
How Halozyme Therapeutics Inc. (RV7) stock reacts to stronger dollarJuly 2025 EndofMonth & Low Drawdown Momentum Ideas - newser.com
Halozyme Therapeutics: Q3 Earnings Snapshot - New Haven Register
Is Halozyme Therapeutics Inc. (RV7) stock dividend growth reliableWeekly Trade Analysis & Daily Oversold Stock Bounce Ideas - newser.com
Halozyme Rides Strong Royalty Growth To Lift Its Outlook - Finimize
Halozyme Q3 2025 slides: royalty revenue surges 52%, guidance raised on strong growth By Investing.com - Investing.com South Africa
Decoding Halozyme Therapeutics Inc (HALO): A Strategic SWOT Insi - GuruFocus
Decoding Halozyme Therapeutics Inc (HALO): A Strategic SWOT Insight - GuruFocus
Halozyme Therapeutics Inc (HALO) Q3 2025 Earnings Call Highlights: Record Royalty Revenue and ... - Yahoo Finance
Halozyme Q3 2025 slides: royalty revenue surges 52%, guidance raised on strong growth - Investing.com Australia
Using Python tools to backtest Halozyme Therapeutics Inc. strategies2025 Trade Ideas & Real-Time Volume Analysis Alerts - newser.com
Why Halozyme Therapeutics Inc. stock is in analyst buy zoneDividend Hike & Stepwise Swing Trade Plans - newser.com
Halozyme Therapeutics (HALO) Reports Record Q3 Revenue Growth - GuruFocus
Transcript : Halozyme Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Earnings call transcript: Halozyme Q3 2025 beats earnings expectations By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo! Finance Australia
Halozyme (HALO) Q3 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Halozyme Q3 2025 beats earnings expectations - Investing.com
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates - Yahoo! Finance Australia
Halozyme Therapeutics Q3 2025 Earnings: Revenue Surpasses Estima - GuruFocus
Halozyme Raises 2025 Guidance After Strong Q3 Results - TipRanks
Halozyme Therapeutics, Inc. Q3 Profit Increases, Beats Estimates - Nasdaq
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS - PR Newswire
Can Halozyme Therapeutics Inc. stock continue upward trendJuly 2025 Market Mood & Risk Managed Investment Strategies - newser.com
What insider trading reveals about Halozyme Therapeutics Inc. stockTrade Entry Report & Entry Point Strategy Guides - newser.com
Strategies to average down on Halozyme Therapeutics Inc.Market Trend Report & Verified Stock Trade Ideas - newser.com
Tools to assess Halozyme Therapeutics Inc.’s risk profileJuly 2025 Patterns & Safe Entry Momentum Tips - newser.com
Exit strategy if you’re trapped in Halozyme Therapeutics Inc.Exit Point & AI Powered Buy/Sell Recommendations - newser.com
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersPortfolio Update Summary & Stepwise Swing Trade Plans - newser.com
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesDollar Strength & Free High Accuracy Swing Entry Alerts - newser.com
Torray Investment Partners LLC Has $2.08 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Why Halozyme Therapeutics Inc. stock could be next big winner2025 Momentum Check & Safe Capital Preservation Plans - newser.com
Assetmark Inc. Raises Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Arkadios Wealth Advisors Acquires 11,457 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Will Halozyme Therapeutics Inc. stock benefit from infrastructure spendingIPO Watch & Risk Managed Investment Strategies - newser.com
Will Halozyme Therapeutics Inc. price bounce be sustainableJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
Will Halozyme Therapeutics Inc. stock benefit from upcoming earnings reportsQuarterly Portfolio Review & AI Driven Price Predictions - newser.com
Halozyme Therapeutics (HALO) Anticipates Strong Q3 Earnings Grow - GuruFocus
Will Halozyme Therapeutics Inc. stock see PE expansionMarket Activity Report & High Accuracy Investment Signals - newser.com
Combining price and volume data for Halozyme Therapeutics Inc.2025 Price Targets & Low Risk Entry Point Tips - newser.com
Retirement Systems of Alabama Sells 4,246 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
AlphaQuest LLC Purchases 5,133 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALOZYME THERAPEUTICS Earnings Preview: Recent $HALO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Sale |
75.35 |
20,000 |
1,507,024 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Sale |
71.20 |
20,000 |
1,424,083 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Sale |
69.03 |
20,000 |
1,380,638 |
733,719 |
| Connaughton Bernadette | Director |
Oct 01 '25 |
Sale |
75.24 |
2,000 |
150,481 |
44,952 |
1.45%
0.86%
자본화:
|
볼륨(24시간):